| Mrs Samantha Ann Undari-schwartz, NP | |
|
301 E Main St, Bay Shore, NY 11706-8408 | |
| (516) 330-1578 | |
| Not Available |
| Full Name | Mrs Samantha Ann Undari-schwartz |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Adult Health |
| Location | 301 E Main St, Bay Shore, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912347428 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | 306519 (New York) | Primary |
| Entity Name | Physical Medicine & Rehabilitation Of Long Island Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003293366 PECOS PAC ID: 4486966157 Enrollment ID: O20150709000313 |
News Archive
One of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine.
An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys.
Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.
ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the three months ended March 31, 2010 and updated the Company's continued progress with its clinical programs.
› Verified 8 days ago
| Entity Name | Olaf Butchma Do Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164054524 PECOS PAC ID: 5597183244 Enrollment ID: O20200914000864 |
News Archive
One of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine.
An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys.
Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.
ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the three months ended March 31, 2010 and updated the Company's continued progress with its clinical programs.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Samantha Ann Undari-schwartz, NP Po Box 433, Massapequa, NY 11758-0433 Ph: (516) 330-1578 | Mrs Samantha Ann Undari-schwartz, NP 301 E Main St, Bay Shore, NY 11706-8408 Ph: (516) 330-1578 |
News Archive
One of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine.
An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys.
Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.
ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the three months ended March 31, 2010 and updated the Company's continued progress with its clinical programs.
› Verified 8 days ago
Richard Kaiser, Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 301 E Main St, Bay Shore, NY 11706 Phone: 631-968-3000 |